SL Science Holding Ltd has completed its business combination and commenced Nasdaq trading, signaling a transition to a publicly traded biotech focused on next-generation allogeneic cell therapies. Its core assets include exclusive global licenses for bispecific antibody-armed T cells (Armed-T) targeting blood cancers and Gamma Delta T cell therapies aimed at pancreatic and brain cancers. While continuing legacy exosome and plant extract sales in Taiwan, SL Science is prioritizing expansion in immuno-oncology through R&D investments, manufacturing process optimization, and regulatory preparations. Growth prospects hinge on clinical milestone achievements, regulatory pathways, licensing expansions, and scaling manufacturing with CDMO partners amid typical early-stage biotech risks.